The reliability of PD-L1 status alone as a predictive biomarker for nivolumab response is still under debate as contradictory results have been published in retrospective studies of NSCLC, urothelial carcinoma, melanoma, and esophageal cancer [5]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.